share_log

Resverlogix Announces Publication of Its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Resverlogix Announces Publication of Its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Resverlogix宣佈發表其關於Apabetalone潛在治療益處的第40篇科學期刊文章
newsfile ·  01/11 20:15

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation," by Dr. Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40th peer-reviewed scientific journal article published by Resverlogix researchers on apabetalone's potential therapeutic benefits.

艾伯塔省卡爾加里--(Newsfile Corp.,2024年1月11日)——Resverlogix Corp.(多倫多證券交易所股票代碼:RVX)(“Resverlogix”,“公司”)今天宣佈發表一篇題爲” 的文章BET 抑制劑 apabetalone 可降低體外和小鼠全身性炎症模型中神經內皮促炎的激活,“由西爾維亞·瓦西亞克博士及其同事在《轉化神經科學》雜誌上撰寫。本出版物標誌着 40第四 由Resverlogix研究人員發表的關於阿帕貝塔隆潛在治療益處的同行評審科學期刊文章。

Apabetalone's Publication Record:

Apabetalone的出版記錄:

  • Articles on apabetalone have been published in some of the world's most prestigious scientific journals, including: Nature, Science, Cell, the Journal of the American Medical Association, Cardiovascular Diabetology and the Clinical Journal of the American Society of Nephrologists

  • Resverlogix researchers and our collaborators have published 40 articles on apabetalone in scientific journals, and including work by third-party researchers, there are more than 100 articles on apabetalone in the academic literature

  • This body of work presents evidence of apabetalone's potential in the treatment of cardiovascular disease, diabetes, post-COVID-19 conditions, chronic kidney disease, and vascular cognitive impairment, as well as rare diseases such as pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, and Fabry's disease

  • The publications also cover a wide spectrum of topics from investigations of apabetalone's mechanism of action at a molecular level, to reports on large-scale clinical trials with thousands of participants

  • 有關阿帕貝塔隆的文章已發表在一些世界上最負盛名的科學期刊上,包括:《自然》、《科學》、《細胞》、《美國醫學會雜誌》、《心血管糖尿病學》和《美國腎臟科醫生學會臨床雜誌》

  • Resverlogix的研究人員和我們的合作者已經在科學期刊上發表了40篇關於阿帕貝他隆的文章,包括第三方研究人員的研究,學術文獻中有100多篇關於阿帕貝他隆的文章

  • 這一系列研究爲阿帕貝他酮在治療心血管疾病、糖尿病、COVID-19後疾病、慢性腎臟病和血管認知障礙以及肺動脈高壓、面肩肱肌營養不良症和法布里氏病等罕見疾病方面的潛力提供了證據

  • 這些出版物還涵蓋了廣泛的主題,從分子層面研究阿帕貝他酮的作用機制到有數千名參與者參與的大規模臨床試驗報告

"We are very proud of our publication record on apabetalone," said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. "Thanks to the dedicated work of our researchers, we have learned an incredible amount about this drug; how it works, why it's safe, and how it can potentially benefit people suffering from chronic disease."

Resverlogix首席科學官埃維琳娜·庫利科夫斯基博士說:“我們爲我們在apabetalone上的出版記錄感到非常自豪。”“多虧了我們研究人員的敬業工作,我們已經學到了很多關於這種藥物的知識;它的工作原理,爲什麼安全,以及它如何可能使慢性病患者受益。”

"The depth and breadth of our knowledge of apabetalone is on full display in the forty scientific articles that we have published to date," said Donald McCaffrey, President and CEO at Resverlogix. "We firmly believe that apabetalone will help chronic disease patients, we have published an extraordinary amount of evidence that supports our belief, and we are looking forward to conclusively demonstrating it in our upcoming, Phase 3, cardiovascular disease trial, BETonMACE2."

Resverlogix總裁兼首席執行官唐納德·麥卡弗裏表示:“我們迄今爲止發表的四十篇科學文章充分體現了我們對阿帕貝塔隆知識的深度和廣度。”“我們堅信阿帕貝他隆將幫助慢性病患者,我們已經發布了大量支持我們信念的證據,我們期待在即將到來的心血管疾病3期試驗BetonMace2中最終證明這一點。”

Highlights from our Latest Publication:

我們最新出版物的亮點:

  • Inflammation in the small blood vessels of the brain is linked to cognitive impairment and decline

  • Using cultured human brain endothelial cells and monocytes, the authors studied apabetalone's effects on inflammation in these small vessels

  • They found that apabetalone treatment reduced the production of pro-inflammatory molecules and cell-cell interactions

  • Their findings were confirmed in a mouse model of brain inflammation, where apabetalone decreased the expression of pro-inflammatory genes

  • By lessening inflammation in the small blood vessels of the brain, apabetalone may help prevent or treat vascular cognitive impairment

  • 大腦小血管發炎與認知障礙和認知能力下降有關

  • 作者使用培養的人腦內皮細胞和單核細胞,研究了apabetalone對這些小血管炎症的影響

  • 他們發現阿巴貝塔隆治療減少了促炎分子的產生和細胞間的相互作用

  • 他們的發現得到了腦部炎症小鼠模型的證實,在該模型中,阿帕貝他隆降低了促炎基因的表達

  • 通過減輕大腦小血管的炎症,阿帕貝他隆可能有助於預防或治療血管認知障礙

Our latest article is published online HERE.

我們的最新文章在這裏在線發佈。

About Apabetalone

關於 Apabetalone

Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes.

Apabetalone(RVX-208)是同類首創的小分子候選治療藥物,具有表觀遺傳學作用機制。它是一種BD2(溴結構域)選擇性BET(溴結構域和外末端)抑制劑,通過調節致病基因的表達來預防和治療疾病。

Due to the extensive role for BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes representing a new way to treat chronic disease. Apabetalone is the only drug of its class that is well tolerated for chronic administration, with an established safety record across multiple human clinical trials, totaling over 4200 patient-years of safety data.

由於BET蛋白在人體中的廣泛作用,apabetalone可以同時靶向多種與疾病相關的生物過程,這是一種治療慢性病的新方法。Apabetalone是同類藥物中唯一一種長期給藥耐受性良好的藥物,在多項人體臨床試驗中都有良好的安全記錄,共有超過4200名患者年的安全數據。

Cardiology:

心臟病學:

Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food & Drug Administration for a major cardiovascular indication. This followed the ground-breaking findings from its Phase 3 study, BETonMACE, which showed apabetalone may prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.

Apabetalone是同類藥物中第一種因主要心血管適應症獲得美國食品藥品監督管理局突破性療法稱號的療法。在此之前,其3期研究BetonMace取得了開創性的發現,該研究表明,在同時患有2型糖尿病的高危心血管疾病患者中,阿帕貝他酮可以預防重大的心臟不良事件。

About Resverlogix

關於 Resverlogix

Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix成立於2001年,是一家總部位於卡爾加里的後期生物技術公司,也是表觀遺傳學領域的全球領導者,目標是開發一流的療法,使慢性病患者受益。

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.

Resverlogix正在開發一類新的表觀遺傳學療法,旨在調節致病基因的表達。我們的目標是通過將因心血管疾病等嚴重疾病而改變的生物學功能恢復到更健康的狀態來改善患者的生活。

The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.

該公司的臨床項目側重於評估用於治療心血管疾病、相關合並症和 COVID-19 後疾病的主要表觀遺傳學候選藥物阿帕貝塔隆。

Resverlogix has partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Resverlogix已與全球生命科學行業下一代商業服務的先驅EVERSANA合作,以支持加拿大和美國治療心血管疾病、COVID-19 後疾病和肺動脈高壓的阿帕貝他隆的快速商業化。

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Resverlogix普通股在多倫多證券交易所(多倫多證券交易所股票代碼:RVX)上市。

Follow us: Twitter: @Resverlogix_RVX. LinkedIn: .

關注我們:推特:@Resverlogix_RVX。領英:。

Forward-Looking Statements:

前瞻性陳述:

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, diabetes, chronic kidney disease, vascular cognitive impairment, COVID-19, post COVID-19 conditions, pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, Fabry's disease, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本新聞稿可能包含適用的加拿大證券立法所定義的某些前瞻性信息,這些信息並非基於歷史事實,包括但不限於包含 “相信”、“預期”、“計劃”、“打算”、“將”、“應該”、“期望”、“繼續”、“估計”、“預測” 和其他類似表述的陳述。特別是,本新聞稿包括與apabetalone在心血管疾病,糖尿病,慢性腎臟病患者治療中的潛在作用有關的前瞻性信息, 血管認知障礙,COVID-19,COVID-19 後病症, 肺動脈高壓、面肩肱肌營養不良症、法布里氏病、相關合並症和其他慢性疾病。我們的實際業績、事件或事態發展可能與這些前瞻性陳述所表達或暗示的業績、事件或事態發展存在重大差異。我們無法保證任何事件或期望會發生或實現。就其性質而言,前瞻性陳述受許多假設和風險因素的約束,包括我們的年度信息表和最新的MD&A中討論的假設和風險因素,這些假設和風險因素以引用方式納入此處,可通過SEDAR獲得,網址爲。本新聞稿中包含的前瞻性陳述受本警示聲明的明確限制,並自本新聞稿發佈之日起作出。除非法律要求,否則公司無意更新或修改任何前瞻性陳述,也沒有義務或責任更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。

For further information please contact:

欲了解更多信息,請聯繫:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

投資者關係
電子郵件:ir@resverlogix.com
電話:403-254-9252

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論